SCHEMBL374649

SCHEMBL374649

BrCc1ccc(-c2ncon2)cc1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.37
PPARA Q07869 1/20 0.34
TRPA1 O75762 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
ADRB2 P07550 1/20 0.33
PDE10A Q9Y233 1/20 0.33
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
SLC2A1 P11166 1/20 0.32
GPR119 Q8TDV5 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
FAAH O00519 1/20 0.30
KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25447823 0.81 ADRB2 (0.55) KMOALDH1A1ADRB2
SCHEMBL17316284 0.78 S1PR1 (0.44) KMOPPARAALDH1A1TSHRCES1
SCHEMBL16907809 0.78 NR1H4 (0.44) KMOPPARAALDH1A1
SCHEMBL17316434 0.75 GAA (0.50) ALDH1A1TSHRADORA2AADORA1
SCHEMBL28481167 0.74 RAB9A (0.46) KMOPPARAALDH1A1TSHRADORA2A
SCHEMBL2740475 0.74 NPC1 (0.40) KMOPPARATSHR
SCHEMBL1188116 0.74 MEN1 (0.50) KMOPPARAALDH1A1
SCHEMBL19356875 0.74 KMO (0.40) KMOPPARAPDE10ASLC2A1GPR119
SCHEMBL3398203 0.74 KMO (0.47) KMOTSHRSLC2A1FAAHKCNH2
SCHEMBL310990 0.73 PSEN1 (0.41) KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332459-B2 Benzimidazole derivatives and their uses TEIJIN PHARMA LIMITED (JP) 2022-05-17 US disclosed
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2020-10-01 US disclosed
EP-2408756-B1 ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2013-05-15 EP disclosed
EP-2408756-A1 ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES Bristol-Myers Squibb Company (US) 2012-01-25 EP disclosed
US-7977362-B2 Alpha-(N-benzenesulfonamido)cycloalkyl derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2011-07-12 US disclosed
US-20110059940-A1 2-Aryl Glycinamide Derivatives BRISTOL- MYERS SQUIBB COMPANY 2011-03-10 US disclosed
EP-2278878-A1 2-ARYL GLYCINAMIDE DERIVATIVES Bristol-Myers Squibb Company (US) 2011-02-02 EP disclosed
WO-2010108067-A1 ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-23 WO disclosed
US-20100240708-A1 Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives BRISTOL-MYERS SQUIBB COMPANY 2010-09-23 US disclosed
WO-2009137657-A1 2-ARYL GLYCINAMIDE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-12 WO disclosed
EP-0086946-B1 AZOLYLSTYRYL COMPOUNDS BAYER AG (DE) 1986-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240708-A1 Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives BACE1, BACE2, APP KMO 1080/4885PPARA 1369/4885TRPA1 2534/4885
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES TRPC6, TRPV6, TRPM6 KMO 2116/4885PPARA 2443/4885TRPA1 13/4885
US-20110059940-A1 2-Aryl Glycinamide Derivatives IAPP, APP, BACE1 KMO 4394/4885PPARA 2197/4885TRPA1 4373/4885
US-11332459-B2 Benzimidazole derivatives and their uses TRPC6, TRPV6, TRPM6 KMO 2116/4885PPARA 2443/4885TRPA1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.